Fig. 4From: Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapyExposure-response for efficacy by dose level in melanoma. a Probability of OR vs Cminss, overall and by dose. b Probability of OR vs CL, overall and by dose. CL = clearance; Cminss = steady-state trough concentration; OR = objective responseBack to article page